141 related articles for article (PubMed ID: 11989799)
1. Syntheses, chemical and enzymatic stability of new poly(ethylene glycol)-acyclovir prodrugs.
Zacchigna M; Di Luca G; Maurich V; Boccù E
Farmaco; 2002 Mar; 57(3):207-14. PubMed ID: 11989799
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of acyclovir in the cat.
Owens JG; Nasisse MP; Tadepalli SM; Dorman DC
J Vet Pharmacol Ther; 1996 Dec; 19(6):488-90. PubMed ID: 8971679
[No Abstract] [Full Text] [Related]
3. Synthesis and evaluation of 2-amino-6-fluoro-9-(2-hydroxyethoxymethyl)purine esters as potential prodrugs of acyclovir.
Kim DK; Lee N; Im GJ; Kim HT; Kim KH
Bioorg Med Chem; 1998 Dec; 6(12):2525-30. PubMed ID: 9925308
[TBL] [Abstract][Full Text] [Related]
4. Acyclovir-valaciclovir equilibrium between peritoneal fluid and plasma.
Stathoulopoulou F; Dhillon S; Stathakis C; Stamatiadis D
Perit Dial Int; 2001; 21(6):614-7. PubMed ID: 11783773
[No Abstract] [Full Text] [Related]
5. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy.
Steingrimsdottir H; Gruber A; Palm C; Grimfors G; Kalin M; Eksborg S
Antimicrob Agents Chemother; 2000 Jan; 44(1):207-9. PubMed ID: 10602752
[TBL] [Abstract][Full Text] [Related]
6. Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.
Smiley ML; Murray A; de Miranda P
Adv Exp Med Biol; 1996; 394():33-9. PubMed ID: 8815698
[No Abstract] [Full Text] [Related]
7. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.
Garré B; Shebany K; Gryspeerdt A; Baert K; van der Meulen K; Nauwynck H; Deprez P; De Backer P; Croubels S
Antimicrob Agents Chemother; 2007 Dec; 51(12):4308-14. PubMed ID: 17846132
[TBL] [Abstract][Full Text] [Related]
8. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS.
Dias C; Nashed Y; Atluri H; Mitra A
Curr Eye Res; 2002 Oct; 25(4):243-52. PubMed ID: 12658558
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.
Weller S; Blum MR; Doucette M; Burnette T; Cederberg DM; de Miranda P; Smiley ML
Clin Pharmacol Ther; 1993 Dec; 54(6):595-605. PubMed ID: 8275615
[TBL] [Abstract][Full Text] [Related]
10. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.
Sinko PJ; Balimane PV
Biopharm Drug Dispos; 1998 May; 19(4):209-17. PubMed ID: 9604120
[TBL] [Abstract][Full Text] [Related]
11. Lack of interaction between valaciclovir, the L-valyl ester of acyclovir, and Maalox antacid.
de Bony F; Bidault R; Peck R; Posner J
J Antimicrob Chemother; 1996 Feb; 37(2):383-7. PubMed ID: 8707752
[TBL] [Abstract][Full Text] [Related]
12. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.
Anand B; Nashed Y; Mitra A
Curr Eye Res; 2003; 26(3-4):151-63. PubMed ID: 12815543
[TBL] [Abstract][Full Text] [Related]
13. Vitreous penetration of orally administered valacyclovir.
Huynh TH; Johnson MW; Comer GM; Fish DN
Am J Ophthalmol; 2008 Apr; 145(4):682-6. PubMed ID: 18226802
[TBL] [Abstract][Full Text] [Related]
14. A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein.
Kim I; Song X; Vig BS; Mittal S; Shin HC; Lorenzi PJ; Amidon GL
Mol Pharm; 2004; 1(2):117-27. PubMed ID: 15832508
[TBL] [Abstract][Full Text] [Related]
15. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.
Han HK; Oh DM; Amidon GL
Pharm Res; 1998 Sep; 15(9):1382-6. PubMed ID: 9755889
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.
Wang LH; Schultz M; Weller S; Smiley ML; Blum MR
Antimicrob Agents Chemother; 1996 Jan; 40(1):80-5. PubMed ID: 8787884
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of new antiherpes agents: famciclovir and valacyclovir.
Stein GE
J Am Pharm Assoc (Wash); 1997; NS37(2):157-63. PubMed ID: 9069689
[TBL] [Abstract][Full Text] [Related]
18. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.
Beutner KR
Antiviral Res; 1995 Dec; 28(4):281-90. PubMed ID: 8669888
[TBL] [Abstract][Full Text] [Related]
19. Stability of valacyclovir: implications for its oral bioavailability.
Granero GE; Amidon GL
Int J Pharm; 2006 Jul; 317(1):14-8. PubMed ID: 16759825
[TBL] [Abstract][Full Text] [Related]
20. Valacyclovir for herpes simplex encephalitis.
Pouplin T; Pouplin JN; Van Toi P; Lindegardh N; Rogier van Doorn H; Hien TT; Farrar J; Török ME; Chau TT
Antimicrob Agents Chemother; 2011 Jul; 55(7):3624-6. PubMed ID: 21576427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
